Search

Your search keyword '"Masjuan, Jaime"' showing total 381 results
Start Over Author "Masjuan, Jaime"
381 results on '"Masjuan, Jaime"'

51. Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study

Author

Universidad de Sevilla. Departamento de Medicina, Sánchez, Manuel Anguita, Marín, Francisco, Masjuan, Jaime, Cosín-Sales, Juan, Vázquez Rodríguez, José Manuel, Barrios, Vivencio, Barón-Esquivias, Gonzalo, Fernández, Marcelo Sanmartín, Universidad de Sevilla. Departamento de Medicina, Sánchez, Manuel Anguita, Marín, Francisco, Masjuan, Jaime, Cosín-Sales, Juan, Vázquez Rodríguez, José Manuel, Barrios, Vivencio, Barón-Esquivias, Gonzalo, and Fernández, Marcelo Sanmartín

Abstract

Background: The aim of this study was to analyze the impact of the presence of heart failure (HF) on the clinical profile and outcomes in patients with atrial fibrillation (AF) anticoagulated with rivaroxaban. Methods: Observational and non-interventional study that included AF adults recruited from 79 Spanish centers, anticoagulated with rivaroxaban ≥ 6 months before inclusion. Data were analyzed according to baseline HF status. Results: Out of 1,433 patients, 326 (22.7%) had HF at baseline. Compared to patients without HF, HF patients were older (75.3 ± 9.9 vs. 73.8 ± 9.6 years; p = 0.01), had more diabetes (36.5% vs. 24.3%; p < 0.01), coronary artery disease (28.2% vs. 12.9%; p < 0.01), renal insufficiency (31.7% vs. 22.6%; p = 0.01), higher CHA2DS2-VASc (4.5 ± 1.6 vs. 3.2 ± 1.4; p < 0.01) and HAS-BLED (1.8 ± 1.1 vs. 1.5 ± 1.0; p < 0.01). After a median follow-up of 2.5 years, among HF patients, annual rates of stroke/ /systemic embolism/transient ischemic attack, major adverse cardiovascular events (MACE) (non-fatal myocardial infarction, revascularization and cardiovascular death), cardiovascular death, and major bleeding were 1.2%, 3.0%, 2.0%, and 1.4%, respectively. Compared to those patients without HF, HF patients had greater annual rates of MACE (3.0% vs. 0.5%; p < 0.01) and cardiovascular death (2.0% vs. 0.2%; p < 0.01), without significant differences regarding other outcomes, including thromboembolic or bleeding events. Previous HF was an independent predictor of MACE (odds ratio 3.4; 95% confidence interval 1.6–7.3; p = 0.002) but not for thromboembolic events or major bleeding. Conclusions: Among AF patients anticoagulated with rivaroxaban, HF patients had a worse clinical profile and a higher MACE risk and cardiovascular mortality. HF was independently associated with the development of MACE, but not with thromboembolic events or major bleeding. (Cardiol J 2022; 29, 6: 936–947).

Published
2022

52. GRECOS Project (Genotyping Recurrence Risk of Stroke): The Use of Genetics to Predict the Vascular Recurrence After Stroke

Author

Fernández-Cadenas, Israel, Mendióroz, Maite, Giralt, Dolors, Nafria, Cristina, Garcia, Elena, Carrera, Caty, Gallego-Fabrega, Cristina, Domingues-Montanari, Sophie, Delgado, Pilar, Ribó, Marc, Castellanos, Mar, Martínez, Sergi, Freijo, Marimar, Jiménez-Conde, Jordi, Rubiera, Marta, Alvarez-Sabín, José, Molina, Carlos A., Font, Maria Angels, Grau Olivares, Marta, Palomeras, Ernest, Perez de la Ossa, Natalia, Martinez-Zabaleta, Maite, Masjuan, Jaime, Moniche, Francisco, Canovas, David, Piñana, Carlos, Purroy, Francisco, Cocho, Dolores, Navas, Inma, Tejero, Carlos, Aymerich, Nuria, Cullell, Natalia, Muiño, Elena, Serena, Joaquín, Rubio, Francisco, Davalos, Antoni, Roquer, Jaume, Arenillas, Juan Francisco, Martí-Fábregas, Joan, Keene, Keith, Chen, Wei-Min, Worrall, Bradford, Sale, Michele, Arboix, Adrià, Krupinski, Jerzy, and Montaner, Joan

Published
2017
Full Text
View/download PDF

54. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

Author

Fernández-Velasco, José I., primary, Monreal, Enric, additional, Kuhle, Jens, additional, Meca-Lallana, Virginia, additional, Meca-Lallana, José, additional, Izquierdo, Guillermo, additional, Oreja-Guevara, Celia, additional, Gascón-Giménez, Francisco, additional, Sainz de la Maza, Susana, additional, Walo-Delgado, Paulette E., additional, Lapuente-Suanzes, Paloma, additional, Maceski, Aleksandra, additional, Rodríguez-Martín, Eulalia, additional, Roldán, Ernesto, additional, Villarrubia, Noelia, additional, Saiz, Albert, additional, Blanco, Yolanda, additional, Diaz-Pérez, Carolina, additional, Valero-López, Gabriel, additional, Diaz-Diaz, Judit, additional, Aladro, Yolanda, additional, Brieva, Luis, additional, Íñiguez, Cristina, additional, González-Suárez, Inés, additional, Rodríguez de Antonio, Luis A, additional, García-Domínguez, José M., additional, Sabin, Julia, additional, Llufriu, Sara, additional, Masjuan, Jaime, additional, Costa-Frossard, Lucienne, additional, and Villar, Luisa M., additional

Published
2022
Full Text
View/download PDF

56. Stroke in Commercial Flights

Author

Álvarez-Velasco, Rodrigo, Masjuan, Jaime, DeFelipe, Alicia, Corral, Iñigo, Estévez-Fraga, Carlos, Crespo, Leticia, and Alonso-Cánovas, Araceli

Published
2016
Full Text
View/download PDF

57. Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

Author

Walo-Delgado, Paulette Esperanza, primary, Monreal, Enric, additional, Medina, Silvia, additional, Quintana, Ester, additional, Sainz de la Maza, Susana, additional, Fernández-Velasco, José Ignacio, additional, Lapuente, Paloma, additional, Comabella, Manuel, additional, Ramió-Torrentà, Lluis, additional, Montalban, Xavier, additional, Midaglia, Luciana, additional, Villarrubia, Noelia, additional, Carrasco-Sayalero, Angela, additional, Rodríguez-Martín, Eulalia, additional, Roldán, Ernesto, additional, Meca-Lallana, José, additional, Alvarez-Lafuente, Roberto, additional, Masjuan, Jaime, additional, Costa-Frossard, Lucienne, additional, and Villar, Luisa Maria, additional

Published
2021
Full Text
View/download PDF

59. Methods of Implementation of Evidence-Based Stroke Care in Europe: European Implementation Score Collaboration

Author

Di Carlo, Antonio, Pezzella, Francesca Romana, Fraser, Alec, Bovis, Francesca, Baeza, Juan, McKevitt, Chris, Boaz, Annette, Heuschmann, Peter, Wolfe, Charles D.A., Inzitari, Domenico, Thijs, Vincent, Rudd, Anthony, Boaz, Annette, Giroud, Maurice, Bejot, Yannick, Wiedmann, Silke, Hermanek, Peter, Wagner, Markus, Baldereschi, Marzia, Lamassa, Maria, Romani, Ilaria, Nencini, Patrizia, Rastenyte, Daiva, Ryglewicz, Danuta, Czlonkowska, Anna, Niewada, Maciej, Dennis, Martin, Gallofré, Miquel, Abilleira, Sonia, Masjuan, Jaime, Norrving, Bo, and Asplund, Kjell

Published
2015
Full Text
View/download PDF

60. Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study.

Author

Sánchez, Manuel Anguita, Marín, Francisco, Masjuan, Jaime, Cosín-Sales, Juan, Vázquez Rodríguez, José Manuel, Barrios, Vivencio, Barón-Esquivias, Gonzalo, Lekuona, Iñaki, Pérez-Cabeza, Alejandro I., Freixa-Pamias, Román, Jimenez, Francisco Javier Parra, Khatib, Mohamed Monzer Khanji, Priu, Carles Rafols, and Fernández, Marcelo Sanmartín

Published
2022
Full Text
View/download PDF

61. Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis

Author

Picón, Carmen, primary, Tejeda-Velarde, Amalia, additional, Fernández-Velasco, José Ignacio, additional, Comabella, Manuel, additional, Álvarez-Lafuente, Roberto, additional, Quintana, Ester, additional, Sainz de la Maza, Susana, additional, Monreal, Enric, additional, Villarrubia, Noelia, additional, Álvarez-Cermeño, José Carlos, additional, Domínguez-Mozo, María Inmaculada, additional, Ramió-Torrentà, Lluís, additional, Rodríguez-Martín, Eulalia, additional, Roldán, Ernesto, additional, Aladro, Yolanda, additional, Medina, Silvia, additional, Espiño, Mercedes, additional, Masjuan, Jaime, additional, Matute-Blanch, Clara, additional, Muñoz-San Martín, Marta, additional, Espejo, Carmen, additional, Guaza, Carmen, additional, Muriel, Alfonso, additional, Costa-Frossard, Lucienne, additional, and Villar, Luisa María, additional

Published
2021
Full Text
View/download PDF

62. Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab

Author

Walo-Delgado, Paulette Esperanza, Monreal, Enric, Medina, Silvia, Quintana, Ester, Sainz de la Maza, Susana, Fernández-Velasco, José Ignacio, Lapuente, Paloma, Comabella, Manuel, Ramió-Torrentà, Lluís, Montalban, Xavier, Midaglia, Luciana, Villarrubia, Noelia, Carrasco-Sayalero, Angela, Rodríguez-Martín, Eulalia, Roldán, Ernesto, Meca-Lallana, José, Alvarez-Lafuente, Roberto, Masjuan, Jaime, Costa-Frossard, Lucienne, Villar, Luisa M, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Walo-Delgado PE, Medina S, Fernández-Velasco JI] Department of Immunology, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain. [Monreal E, Sainz de la Maza S] Department of Neurology, Ramón y Cajal University Hospital, IRYCIS, Red Española de Esclerosis Múltiple (REEM), Madrid, Spain. [Quintana E] Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Neurodegeneration and Neuroinflammation Research Group, Biomedical Research Institute (IDIBGI), Red Española de Esclerosis Múltiple (REEM), Girona, Spain. [Comabella M, Montalban X, Midaglia L] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Male, T-Lymphocytes, Autoimmunity, Other subheadings::Other subheadings::/drug therapy [Other subheadings], multiple sclerosis, Gastroenterology, Natalizumab, Interquartile range, alemtuzumab, Immunology and Allergy, Medicine, Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Relapsing-Remitting [DISEASES], Prospective cohort study, Side effects, Alemtuzumab, Original Research, B-Lymphocytes, Autoimmunitat, autoimmunity, Middle Aged, enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple recurrente-remitente [ENFERMEDADES], side effects, disease modifying treatments, Disease modifying treatments, Female, Immunosuppressive Agents, medicine.drug, Adult, medicine.medical_specialty, Cèl·lules B, Immunology, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Cells::Antibody-Producing Cells::B-Lymphocytes [ANATOMY], Multiple sclerosis, Multiple Sclerosis, Relapsing-Remitting, Internal medicine, Humans, Adverse effect, células::células productoras de anticuerpos::linfocitos B [ANATOMÍA], B cells, business.industry, biomarkers, Odds ratio, RC581-607, medicine.disease, Immunologic diseases. Allergy, business, Esclerosi múltiple - Tractament, CD8, Biomarkers
Abstract

Células B; Alemtuzumab; Autoinmunidad Limfòcits B; Alemtuzumab; Autoimmunitat B cells; Alemtuzumab; Autoimmunity Objective: To explore if baseline blood lymphocyte profile could identify relapsing remitting multiple sclerosis (RRMS) patients at higher risk of developing secondary autoimmune adverse events (AIAEs) after alemtuzumab treatment. Methods: Multicenter prospective study including 57 RRMS patients treated with alemtuzumab followed for 3.25 [3.5-4.21] years, (median [interquartile range]). Blood samples were collected at baseline, and leukocyte subsets determined by flow cytometry. We had additional samples one year after the first cycle of alemtuzumab treatment in 39 cases. Results: Twenty-two patients (38.6%) developed AIAEs during follow-up. They had higher B-cell percentages at baseline (p=0.0014), being differences mainly due to plasmablasts/plasma cells (PB/PC, p=0.0011). Those with no AIAEs had higher percentages of CD4+ T cells (p=0.013), mainly due to terminally differentiated (TD) (p=0.034) and effector memory (EM) (p=0.031) phenotypes. AIAEs- patients also showed higher values of TNF-alpha-producing CD8+ T cells (p=0.029). The percentage of PB/PC was the best variable to differentiate both groups of patients. Baseline values >0.10% closely associated with higher AIAE risk (Odds ratio [OR]: 5.91, 95% CI: 1.83-19.10, p=0.004). When excluding the 12 patients with natalizumab, which decreases blood PB/PC percentages, being the last treatment before alemtuzumab, baseline PB/PC >0.1% even predicted more accurately the risk of AIAEs (OR: 11.67, 95% CI: 2.62-51.89, p=0.0007). The AIAEs+ group continued having high percentages of PB/PC after a year of alemtuzumab treatment (p=0.0058). Conclusions: A PB/PC percentage

Published
2021

63. Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: consensus document and practice guidance

Author

Gil-Núñez, Antonio, Masjuan, Jaime, Montaner, Joan, Castellanos, María del Mar, Segura, Tomás, Cardona, Pere, Tembl, José Ignacio, Purroy, Francesc, Arenillas, Juan, Palacio, Enrique, Gil-Núñez, Antonio, Masjuan, Jaime, Montaner, Joan, Castellanos, María del Mar, Segura, Tomás, Cardona, Pere, Tembl, José Ignacio, Purroy, Francesc, Arenillas, Juan, and Palacio, Enrique

Abstract

[Abstract] Introduction: Patients with history of stroke or transient ischaemic attack present considerable risk of future vascular events. Reducing levels of low-density lipoprotein (LDL) cholesterol decreases the incidence of new vascular events, although in a substantial number of patients, the currently available lipid-lowering therapies fail to achieve the therapeutic goals recommended in clinical guidelines. The aim of this consensus statement is to provide updated information on the role of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors alirocumab and evolocumab in the secondary prevention of vascular events in patients with history of ischaemic stroke. Methods: A literature review was performed to identify the main evidence on the use of PCSK9 inhibitors in these patients and the recommended therapeutic targets of LDL cholesterol. The results were discussed in 2 consensus meetings that constituted the basis for the drafting of the document. Conclusions: PCSK9 inhibitors are effective in reducing vascular risk in secondary prevention; evolocumab specifically has achieved this reduction in patients with history of ischaemic stroke. Moreover, both alirocumab and evolocumab present good safety profiles, even in patients achieving LDL cholesterol levels <20 mg/dL, and no signs of cognitive impairment have been observed in patients treated with evolocumab who achieved very low levels of LDL cholesterol. In the light of this evidence, we provide practical recommendations about the use of PCSK9 inhibitors in secondary prevention of vascular events in patients with history of ischaemic stroke and follow-up of these patients., [Resumen] Introducción. Los pacientes, tras un ictus o un ataque isquémico transitorio, presentan un riesgo muy elevado de sufrir nuevos episodios vasculares. La reducción del nivel de colesterol unido a lipoproteínas de baja densidad (cLDL) reduce la incidencia de nuevos episodios, si bien una proporción importante de pacientes no alcanza los objetivos terapéuticos recomendados con los tratamientos hipolipemiantes actuales. El objetivo de este documento de consenso es actualizar el papel de los inhibidores de la proproteína convertasa subtilisina/kexina tipo 9 (iPCSK9; alirocumab y evolocumab) en la prevención secundaria de episodios vasculares en pacientes con ictus isquémico previo. Métodos. Se realizó una revisión bibliográfica para identificar las principales evidencias sobre el uso de iPCSK9 en estos pacientes y los objetivos terapéuticos recomendados de cLDL. Los resultados se discutieron en 2 reuniones de consenso, que constituyeron la base para la elaboración del documento. Conclusiones. Los iPSCSK9 son eficaces en la reducción del riesgo vascular en prevención secundaria y, específicamente, evolocumab ha demostrado esta reducción en pacientes con ictus isquémico previo. Ambos fármacos han demostrado un buen perfil de seguridad, incluso en pacientes que alcanzaron un nivel de cLDL <20 mg/dL. En este sentido, en el subestudio de episodios neurocognitivos con evolocumab no se observó ninguna señal de empeoramiento de la función cognitiva en pacientes con nivel muy bajo de cLDL. Con base en estas evidencias, en el documento se presentan recomendaciones prácticas sobre el uso de iPCSK9 para la prevención secundaria y seguimiento de episodios vasculares en pacientes con ictus isquémico previo.

Published
2021

64. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

Author

Esteve-Pastor, María A, Rivera-Caravaca, José M, Roldán, Vanessa, Sanmartin Fernández, Marcelo, Arribas, Fernando, Masjuan, Jaime, Barrios, Vivencio, Cosin-Sales, Juan, Freixa-Pamias, Román, Recalde, Esther, Pérez-Cabeza, Alejandro I, Manuel Vázquez Rodríguez, José, Ràfols Priu, Carles, Anguita Sánchez, Manuel, Lip, Gregory Y H, and Marin, Francisco

Published
2023
Full Text
View/download PDF

65. Predictive biomarkers to identify an increased risk of autoimmunity in patients treated with alemtuzumab. (4175)

Author

Delgado, Paulette Esperanza Walo, primary, Laguillo, Enric Monreal, additional, Heras, Silvia Medina, additional, Quintana, Ester, additional, de la Maza, Susana Sainz, additional, Torrenta, Lluis Ramio, additional, Velasco, Jose Ignacio Fernandez, additional, Suanzes, Paloma Lapuente, additional, Villarrubia, Noelia, additional, Lopez, Manuel Comabella, additional, Lallana, Jose Meca, additional, Masjuan, Jaime, additional, Frossard, Lucienne Costa, additional, and Villar, Luisa Maria, additional

Published
2021
Full Text
View/download PDF

66. Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS

Author

Fernández-Velasco, José I., primary, Kuhle, Jens, additional, Monreal, Enric, additional, Meca-Lallana, Virginia, additional, Meca-Lallana, José, additional, Izquierdo, Guillermo, additional, Gascón-Giménez, Francisco, additional, Sainz de la Maza, Susana, additional, Walo-Delgado, Paulette E., additional, Maceski, Aleksandra, additional, Rodríguez-Martín, Eulalia, additional, Roldán, Ernesto, additional, Villarrubia, Noelia, additional, Saiz, Albert, additional, Blanco, Yolanda, additional, Sánchez, Pedro, additional, Carreón-Guarnizo, Ester, additional, Aladro, Yolanda, additional, Brieva, Luis, additional, Íñiguez, Cristina, additional, González-Suárez, Inés, additional, Rodríguez de Antonio, Luis A., additional, Masjuan, Jaime, additional, Costa-Frossard, Lucienne, additional, and Villar, Luisa M., additional

Published
2021
Full Text
View/download PDF

67. Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke:The Global COVID-19 Stroke Registry

Author

Ntaios, George, Michel, Patrik, Georgiopoulos, Georgios, Guo, Yutao, Li, Wencheng, Xiong, Jing, Calleja, Patricia, Ostos, Fernando, González-Ortega, Guillermo, Fuentes, Blanca, Alonso de Leciñana, María, Díez-Tejedor, Exuperio, García-Madrona, Sebastian, Masjuan, Jaime, DeFelipe, Alicia, Turc, Guillaume, Gonçalves, Bruno, Domigo, Valerie, Dan, Gheorghe-Andrei, Vezeteu, Roxana, Christensen, Hanne, Christensen, Louisa Marguerite, Meden, Per, Hajdarevic, Lejla, Rodriguez-Lopez, Angela, Díaz-Otero, Fernando, García-Pastor, Andrés, Gil-Nuñez, Antonio, Maslias, Errikos, Strambo, Davide, Werring, David J, Chandratheva, Arvind, Benjamin, Laura, Simister, Robert, Perry, Richard, Beyrouti, Rahma, Jabbour, Pascal, Sweid, Ahmad, Tjoumakaris, Stavropoula, Cuadrado-Godia, Elisa, Campello, Ana Rodríguez, Roquer, Jaume, Moreira, Tiago, Mazya, Michael V, Bandini, Fabio, Matz, Karl, Iversen, Helle K, González-Duarte, Alejandra, Tiu, Cristina, Ferrari, Julia, Vosko, Milan R, Salzer, Helmut J F, Lamprecht, Bernd, Dünser, Martin W, Cereda, Carlo W, Quintero, Ángel Basilio Corredor, Korompoki, Eleni, Soriano-Navarro, Eduardo, Soto-Ramírez, Luis Enrique, Castañeda-Méndez, Paulo F, Bay-Sansores, Daniela, Arauz, Antonio, Cano-Nigenda, Vanessa, Kristoffersen, Espen Saxhaug, Tiainen, Marjaana, Strbian, Daniel, Putaala, Jukka, Lip, Gregory Y H, Ntaios, George, Michel, Patrik, Georgiopoulos, Georgios, Guo, Yutao, Li, Wencheng, Xiong, Jing, Calleja, Patricia, Ostos, Fernando, González-Ortega, Guillermo, Fuentes, Blanca, Alonso de Leciñana, María, Díez-Tejedor, Exuperio, García-Madrona, Sebastian, Masjuan, Jaime, DeFelipe, Alicia, Turc, Guillaume, Gonçalves, Bruno, Domigo, Valerie, Dan, Gheorghe-Andrei, Vezeteu, Roxana, Christensen, Hanne, Christensen, Louisa Marguerite, Meden, Per, Hajdarevic, Lejla, Rodriguez-Lopez, Angela, Díaz-Otero, Fernando, García-Pastor, Andrés, Gil-Nuñez, Antonio, Maslias, Errikos, Strambo, Davide, Werring, David J, Chandratheva, Arvind, Benjamin, Laura, Simister, Robert, Perry, Richard, Beyrouti, Rahma, Jabbour, Pascal, Sweid, Ahmad, Tjoumakaris, Stavropoula, Cuadrado-Godia, Elisa, Campello, Ana Rodríguez, Roquer, Jaume, Moreira, Tiago, Mazya, Michael V, Bandini, Fabio, Matz, Karl, Iversen, Helle K, González-Duarte, Alejandra, Tiu, Cristina, Ferrari, Julia, Vosko, Milan R, Salzer, Helmut J F, Lamprecht, Bernd, Dünser, Martin W, Cereda, Carlo W, Quintero, Ángel Basilio Corredor, Korompoki, Eleni, Soriano-Navarro, Eduardo, Soto-Ramírez, Luis Enrique, Castañeda-Méndez, Paulo F, Bay-Sansores, Daniela, Arauz, Antonio, Cano-Nigenda, Vanessa, Kristoffersen, Espen Saxhaug, Tiainen, Marjaana, Strbian, Daniel, Putaala, Jukka, and Lip, Gregory Y H

Abstract

Recent case-series of small size implied a pathophysiological association between coronavirus disease 2019 (COVID-19) and severe large-vessel acute ischemic stroke. Given that severe strokes are typically associated with poor prognosis and can be very efficiently treated with recanalization techniques, confirmation of this putative association is urgently warranted in a large representative patient cohort to alert stroke clinicians, and inform pre- and in-hospital acute stroke patient pathways. We pooled all consecutive patients hospitalized with laboratory-confirmed COVID-19 and acute ischemic stroke in 28 sites from 16 countries. To assess whether stroke severity and outcomes (assessed at discharge or at the latest assessment for those patients still hospitalized) in patients with acute ischemic stroke are different between patients with COVID-19 and non-COVID-19, we performed 1:1 propensity score matching analyses of our COVID-19 patients with non-COVID-19 patients registered in the Acute Stroke Registry and Analysis of Lausanne Registry between 2003 and 2019. Between January 27, 2020, and May 19, 2020, 174 patients (median age 71.2 years; 37.9% females) with COVID-19 and acute ischemic stroke were hospitalized (median of 12 patients per site). The median National Institutes of Health Stroke Scale was 10 (interquartile range [IQR], 4-18). In the 1:1 matched sample of 336 patients with COVID-19 and non-COVID-19, the median National Institutes of Health Stroke Scale was higher in patients with COVID-19 (10 [IQR, 4-18] versus 6 [IQR, 3-14]), P=0.03; (odds ratio, 1.69 [95% CI, 1.08-2.65] for higher National Institutes of Health Stroke Scale score). There were 48 (27.6%) deaths, of which 22 were attributed to COVID-19 and 26 to stroke. Among 96 survivors with available information about disability status, 49 (51%) had severe disability at discharge. In the propensity score-matched population (n=330), patients with COVID-19 had higher risk for severe disability (med

Published
2020

70. Focal CT hypoperfusion in HaNDL

Author

Barragán, Nuria García, Guillán, Marta, Zarza, Beatriz, González-Gordaliza, Cristina, de Felipe Mimbrera, Alicia, de Leciñana, María Alonso, and Masjuan, Jaime

Published
2012
Full Text
View/download PDF

75. Decompressive Surgery in Cerebrovenous Thrombosis: A Multicenter Registry and a Systematic Review of Individual Patient Data

Author

Ferro, José M., Crassard, Isabelle, Coutinho, Jonathan M., Canhão, Patrícia, Barinagarrementeria, Fernando, Cucchiara, Brett, Derex, Laurent, Lichy, Christoph, Masjuan, Jaime, Massaro, Ayrton, Matamala, Gonzalo, Poli, Sven, Saadatnia, Mohammad, Stolz, Erwin, Viana-Baptista, Miguel, Stam, Jan, and Bousser, Marie-Germaine

Published
2011
Full Text
View/download PDF

76. Neurology at the airport

Author

Alonso-Cánovas, Araceli, de Felipe-Mimbrera, Alicia, González-Valcárcel, Jaime, García-Barragán, Nuria, Corral, Iñigo, and Masjuan, Jaime

Published
2011
Full Text
View/download PDF

78. Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients

Author

Ros-Castelló, Victoria, primary, Natera-Villalba, Elena, additional, Gómez-López, Ana, additional, Sánchez-Sánchez, Arantxa, additional, Chico-García, Juan Luis, additional, García-Madrona, Sebastian, additional, Vera-Lechuga, Rocio, additional, Matute-Lozano, Consuelo, additional, de Felipe Mimbrera, Alicia, additional, Cruz-Culebras, Antonio, additional, Alonso-Canovas, Araceli, additional, and Masjuan, Jaime, additional

Published
2020
Full Text
View/download PDF

79. Long-Term Anticoagulation in Secondary Ischemic Stroke Prevention: The Prospective Multicenter RESTAIC Registry

Author

Gutiérrez-Zúñiga, Raquel, primary, Rigual, Ricardo, additional, Torres-Iglesias, Gabriel, additional, Sánchez-Velasco, Sara, additional, Alonso de Leciñana, María, additional, Masjuan, Jaime, additional, Álvarez Velasco, Rodrigo, additional, Navas, Inmaculada, additional, Izquierdo-Esteban, Laura, additional, Fernández-Ferro, José, additional, Rodríguez-Pardo, Jorge, additional, Ruiz-Ares, Gerardo, additional, Zapata-Wainberg, Gustavo, additional, Fuentes, Blanca, additional, and Díez-Tejedor, Exuperio, additional

Published
2020
Full Text
View/download PDF

80. Non-severe immunosuppression might be associated with a lower risk of moderate-severe acute respiratory distress syndrome in COVID-19.

Author

Monreal, Enric, primary, Maza, Susana Sainz de la, additional, Gullón, Pedro, additional, Natera-Villalba, Elena, additional, Chico-García, Juan Luis, additional, Beltrán-Corbellini, Álvaro, additional, Martínez-Sanz, Javier, additional, García-Barragán, Nuria, additional, Buisán, Javier, additional, Toledano, Rafael, additional, Alonso-Canovas, Araceli, additional, Pérez-Torre, Paula, additional, Matute-Lozano, María Consuelo, additional, López-Sendón, Jose Luis, additional, García-Ribas, Guillermo, additional, Corral, Íñigo, additional, Fortún, Jesús, additional, Montero-Errasquín, Beatriz, additional, Manzano, Luis, additional, Máiz-Carro, Luis, additional, Costa-Frossard, Lucienne, additional, and Masjuan, Jaime, additional

Published
2020
Full Text
View/download PDF

81. Immunosuppression is associated with a lower risk of moderate to severe acute respiratory distress syndrome in COVID-19.

Author

Monreal, Enric, primary, Maza, Susana Sainz de la, additional, Gullón, Pedro, additional, Natera-Villalba, Elena, additional, Chico-García, Juan Luis, additional, Beltrán-Corbellini, Álvaro, additional, Martínez-Sanz, Javier, additional, García-Barragán, Nuria, additional, Buisán, Javier, additional, Toledano, Rafael, additional, Alonso-Canovas, Araceli, additional, Pérez-Torre, Paula, additional, Matute-Lozano, María Consuelo, additional, López-Sendón, Jose Luis, additional, García-Ribas, Guillermo, additional, Corral, Íñigo, additional, Fortún, Jesús, additional, Montero-Errasquín, Beatriz, additional, Manzano, Luis, additional, Máiz-Carro, Luis, additional, Costa-Frossard, Lucienne, additional, and Masjuan, Jaime, additional

Published
2020
Full Text
View/download PDF

82. Progression of carotid near-occlusion to complete occlusion: related factors and clinical implications

Author

García-Pastor, Andrés, primary, Gil-Núñez, Antonio, additional, Ramírez-Moreno, José María, additional, González-Nafría, Noelia, additional, Tejada, Javier, additional, Moniche, Francisco, additional, Portilla-Cuenca, Juan Carlos, additional, Martínez-Sánchez, Patricia, additional, Fuentes, Blanca, additional, Gamero-García, Miguel Ángel, additional, Alonso de Leciñana, María, additional, Masjuan, Jaime, additional, Cánovas, David, additional, Aladro, Yolanda, additional, Parkhutik, Vera, additional, Lago, Aida, additional, De Arce, Ana María, additional, Usero-Ruiz, María, additional, Delgado-Mederos, Raquel, additional, Pampliega, Ana, additional, Ximénez-Carrillo, Álvaro, additional, Bártulos-Iglesias, Mónica, additional, and Castro-Reyes, Enrique, additional

Published
2020
Full Text
View/download PDF

90. Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease

Author

Masjuan, Jaime, Gállego, Jaime, Aguilera, José María, Arenillas, Juan, Castellanos, María del Mar, Díaz, Fernando, Portilla, Juan Carlos, Purroy, Francesc, Masjuan, Jaime, Gállego, Jaime, Aguilera, José María, Arenillas, Juan, Castellanos, María del Mar, Díaz, Fernando, Portilla, Juan Carlos, and Purroy, Francesc

Abstract

[Abstract] Introduction: There is little control of cardiovascular (CV) risk factors in secondary prevention after an ischaemic stroke, in part due to a lack of adherence to treatment. The CV polypill may contribute to proper treatment adherence, which is necessary for CV disease prevention. This study aimed to establish how and in what cases the CV polypill should be administered. Methods: A group of 8 neurologists drafted consensus recommendations using structured brainstorming and based on their experience and a literature review. Results: These recommendations are based on the opinion of the participating experts. The use of the CV polypill is beneficial for patients, healthcare professionals, and the health system. Its use is most appropriate for atherothrombotic stroke, lacunar stroke, stroke associated with cognitive impairment, cryptogenic stroke with CV risk factors, and silent cerebrovascular disease. It is the preferred treatment in cases of suspected poor adherence, polymedicated patients, elderly people, patients with polyvascular disease or severe atherothrombosis, young patients in active work, and patients who express a preference for the CV polypill. Administration options include switching from individual drugs to the CV polypill, starting treatment with the CV polypill in the acute phase in particular cases, use in patients receiving another statin or an angiotensin ii receptor antagonist, or de novo use if there is suspicion of poor adherence. Nevertheless, use of the CV polypill requires follow-up on the achievement of the therapeutic objectives to make dose adjustments. Conclusions: This document is the first to establish recommendations for the use of the CV polypill in cerebrovascular disease, beyond its advantages in terms of treatment adherence., [Resumen] Introducción. El control de los factores de riesgo cardiovascular (CV) en la prevención secundaria tras un ictus isquémico es bajo, en parte debido a la falta de adherencia terapéutica. La polipíldora CV puede contribuir a la buena cumplimentación del adecuado tratamiento para la prevención cerebrovascular. El objetivo fue establecer cómo y en qué casos se debería administrar. Métodos. Un grupo de 8 neurólogos redactaron recomendaciones consensuadas mediante una técnica de brainstorming estructurado, basándose en su experiencia y en una revisión bibliográfica. Resultados. Los resultados atienden a la opinión de los expertos. El uso de la polipíldora CV tiene ventajas para pacientes, profesionales sanitarios y para el sistema de salud. Las situaciones clínicas más adecuadas para su uso son el ictus aterotrombótico, el lacunar, el asociado a deterioro cognitivo, el criptogénico con factores de riesgo CV y la enfermedad cerebrovascular silente. Su uso preferente incluye la sospecha de mal cumplimiento, a los pacientes polimedicados, ancianos, polivasculares o con alta carga aterotrombótica, jóvenes activos laboralmente y pacientes con preferencias por la polipíldora CV. Las opciones de administración incluyen el paso de fármacos individuales a la polipíldora CV, el inicio directo desde la fase aguda en casos particulares, a los pacientes con otra estatina o con un antagonista del receptor de la angiotensina ii, o de novo si hubiera sospecha de mala adherencia. No obstante, su uso implica realizar seguimiento del cumplimiento de los objetivos terapéuticos para ajustar la dosis. Conclusiones. Este documento es el primero en establecer recomendaciones de uso de la polipíldora CV en enfermedad cerebrovascular, aparte de sus ventajas sobre la adherencia.

Published
2019

91. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source

Author

Diener, Hans-Christoph, primary, Sacco, Ralph L., additional, Easton, J. Donald, additional, Granger, Christopher B., additional, Bernstein, Richard A., additional, Uchiyama, Shinichiro, additional, Kreuzer, Jörg, additional, Cronin, Lisa, additional, Cotton, Daniel, additional, Grauer, Claudia, additional, Brueckmann, Martina, additional, Chernyatina, Marina, additional, Donnan, Geoffrey, additional, Ferro, José M., additional, Grond, Martin, additional, Kallmünzer, Bernd, additional, Krupinski, Jerzy, additional, Lee, Byung-Chul, additional, Lemmens, Robin, additional, Masjuan, Jaime, additional, Odinak, Miroslav, additional, Saver, Jeffrey L., additional, Schellinger, Peter D., additional, Toni, Danilo, additional, and Toyoda, Kazunori, additional

Published
2019
Full Text
View/download PDF

92. Age- and Sex-Specific Risk Profiles and In-Hospital Mortality in 13,932 Spanish Stroke Patients

Author

Purroy, Francisco, primary, Vena, Ana, additional, Forné, Carles, additional, de Arce, Ana María, additional, Dávalos, Antonio, additional, Fuentes, Blanca, additional, Arenillas, Juan Francisco, additional, Krupinski, Jerzy, additional, Gómez-Choco, Manuel, additional, Palomeras, Ernest, additional, Martí-Fábregas, Joan, additional, Castillo, José, additional, Ustrell, Xavier, additional, Tejada, Javier, additional, Masjuan, Jaime, additional, Garcés, Moisés, additional, Benabdelhak, Ikram, additional, and Serena, Joaquin, additional

Published
2019
Full Text
View/download PDF

93. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study.

Author

Monreal, Enric, Sainz de la Maza, Susana, Natera-Villalba, Elena, Beltrán-Corbellini, Álvaro, Rodríguez-Jorge, Fernando, Fernández-Velasco, Jose Ignacio, Walo-Delgado, Paulette, Muriel, Alfonso, Zamora, Javier, Alonso-Canovas, Araceli, Fortún, Jesús, Manzano, Luis, Montero-Errasquín, Beatriz, Costa-Frossard, Lucienne, Masjuan, Jaime, Villar, Luisa María, for the COVID-HRC group, Máiz-Carro, L., Sánchez-García, E. M., and Hidalgo, F.

Subjects
COVID-19, ADRENOCORTICAL hormones, CORONAVIRUS disease treatment, CORTICOSTEROIDS, ADULT respiratory distress syndrome, OLDER patients, MIDDLE East respiratory syndrome
Abstract

Despite the increasing evidence of the benefit of corticosteroids for the treatment of moderate-severe coronavirus disease 2019 (COVID-19) patients, no data are available about the potential role of high doses of steroids for these patients. We evaluated the mortality, the risk of need for mechanical ventilation (MV), or death and the risk of developing a severe acute respiratory distress syndrome (ARDS) between high (HD) and standard doses (SD) among patients with a severe COVID-19. All consecutive confirmed COVID-19 patients admitted to a single center were selected, including those treated with steroids and an ARDS. Patients were allocated to the HD (≥ 250 mg/day of methylprednisolone) of corticosteroids or the SD (≤ 1.5 mg/kg/day of methylprednisolone) at discretion of treating physician. Five hundred seventy-three patients were included: 428 (74.7%) men, with a median (IQR) age of 64 (54–73) years. In the HD group, a worse baseline respiratory situation was observed and male gender, older age, and comorbidities were significantly more common. After adjusting by baseline characteristics, HDs were associated with a higher mortality than SD (adjusted OR 2.46, 95% CI 1.59–3.81, p < 0.001) and with an increased risk of needing MV or death (adjusted OR 2.35, p = 0.001). Conversely, the risk of developing a severe ARDS was similar between groups. Interaction analysis showed that HD increased mortality exclusively in elderly patients. Our real-world experience advises against exceeding 1–1.5 mg/kg/day of corticosteroids for severe COVID-19 with an ARDS, especially in older subjects. This reinforces the rationale of modulating rather than suppressing immune responses in these patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

94. The Impact of Immunosuppression and Autoimmune Disease on Severe Outcomes in Patients Hospitalized with COVID-19.

Author

Monreal, Enric, Sainz de la Maza, Susana, Fernández-Velasco, Jose Ignacio, Natera-Villalba, Elena, Rita, Claudia Geraldine, Rodríguez-Jorge, Fernando, Beltrán-Corbellini, Álvaro, Iturrieta-Zuazo, Ignacio, Rodríguez de Santiago, Enrique, Espiño, Mercedes, de Andrés, Ana, Fortún, Jesús, Barbero, Esther, Vázquez, Mónica, Fernández Lucas, Milagros, Manzano, Luis, Montero-Errasquín, Beatriz, Costa-Frossard, Lucienne, Masjuan, Jaime, and Villar, Luisa María

Subjects
COVID-19, AUTOIMMUNE diseases, ADULT respiratory distress syndrome, IMMUNOSUPPRESSION
Abstract

Immunosuppression (IS) and autoimmune disease (AD) are prevalent in patients with severe coronavirus disease 2019 (COVID-19), but their impact on its clinical course is unknown. We investigated relationships between IS, AD, and outcomes in patients hospitalized with COVID-19. Data on consecutive admissions for COVID-19 were extracted retrospectively from medical records. Patients were assigned to one of four cohorts, according to whether or not they had an AD (AD and NAD) or were immunosuppressed (IS and NIS). The primary endpoint was development of severe acute respiratory distress syndrome (ARDS); secondary endpoints included death, and a composite of mechanical ventilation (MV) or death. A total of 789 patients were included: 569 (72.1%) male, 76 (9.6%) with an AD, and 63 (8.0%) with IS. Relative to the NIS-NAD cohort, patients in the IS-AD cohort had a significantly reduced risk of severe ARDS (adjusted hazard ratio [aHR] 0.42; 95% confidence interval [CI] 0.23–0.80; p = 0.008). No significant relationships between IS or AD status and either death or the composite of MV and death were identified, although a trend towards higher mortality was identified in the IS-NAD cohort (aHR vs NIS-NAD 1.71; 95% CI 0.94–3.12; p = 0.081). Patients in this cohort also had higher median serum levels of interleukin-6 compared with IS-AD patients (98.2 vs 21.6 pg/mL; p = 0.0328) and NIS-NAD patients (29.1 pg/mL; p = 0.0057). In conclusion, among patients hospitalized with COVID-19, those receiving immunosuppressive treatment for an AD may have a reduced risk of developing severe ARDS. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

95. On the Way to a Better Use of Anticoagulants in Nonvalvular Atrial Fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT/V4/23122013

Author

Roldán, Inmaculada, Marín, Francisco, Tello-Montoliu, Antonio, Roldán, Vanessa, Anguita, Manuel, Ruiz Nodar, Juan Miguel, Íñiguez, Andrés, González Juanatey, José Ramón, Rodríguez Padial, Luis, Badimón, Lina, Mateo, José, Vicente, Vicente, Gallego Culleré, Jaime, Masjuan, Jaime, González-Armengol, Juan J., Marín-Martínez, Alfonso, Coll-Vinent i Puig, Blanca, Casariego-Vales, Emilio, Llisterri-Caro, José Luis, Polo-García, José, and Rodríguez-Roca, Gustavo C.

Published
2016
Full Text
View/download PDF

96. Factors associated with poor anticoagulation control with vitamin K antagonists among outpatients attended in Internal Medicine and Neurology. The ALADIN study

Author

Contreras Muruaga, M.M., primary, Reig, G., additional, Vivancos, J., additional, González, A., additional, Cardona, P., additional, Ramírez-Moreno, J.M., additional, Martí-Fábregas, J., additional, Suárez Fernández, C., additional, Pose, Antonio, additional, Díaz, José Antonio, additional, Rodríguez, Manuel, additional, Pena, Marta, additional, Arias, Susana, additional, Larrosa, Davinia, additional, González, Álvaro, additional, Rodríguez, Elisa, additional, González, Montserrat, additional, Fernández, Dolores, additional, Barbagelata, Cristina, additional, Raña, Natividad, additional, Freire, Santiago, additional, Cerqueiro, J. Manuel, additional, Guerrero, Héctor, additional, Ramos, Laura, additional, Álvarez, Leticia, additional, de Lis, José M., additional, Caro, Carmen, additional, Seijo, Manuel, additional, Mederer, Susana, additional, de Zarraga, Miguel Alberto, additional, Ferreiro, José, additional, Terrero, José M., additional, Arias, Mónica, additional, Pérez, Roberto, additional, Sánchez, Joaquín, additional, Maciñeiras, José, additional, Fernández, Julián, additional, Jaén, Fernando, additional, Esteva, David, additional, Zamora, Mónica, additional, Navarrete, Nuria, additional, García, Javier, additional, Mérida, Luis, additional, Corrales, Miguel Ángel, additional, Quirós, Raúl, additional, Cantero, Jesús, additional, Barrero, Francisco Javier, additional, Villegas, Inmaculada, additional, Castro, José, additional, Foronda, Jesús, additional, Carrillo, Dionisio, additional, Vega, Jesús, additional, Trujillo, José Antonio, additional, Montero, Manuel, additional, Jurado, Ana, additional, Sánchez, Carlos, additional, Agüera-Morales, Eduardo, additional, Sánchez, María, additional, Durán, Purificación, additional, Fernández de la Puerta, Rafael, additional, Pérez de la Blanca, María, additional, Martínez, María Paz, additional, Fernández, Óscar, additional, Tamayo, José Antonio, additional, Bustamante, Rafael, additional, Serrano, Pedro Jesús, additional, Arjona, Antonio, additional, Fernández, Javier, additional, Payan, Manuel, additional, Gómez, Ricardo, additional, Peña, Daniel, additional, Cabrerizo, Enrique, additional, Salgado, Fernando, additional, Ivanova Georgieva, Radka, additional, Gil-Núñez, Antonio, additional, Bello, Elena, additional, Díaz, Fernando, additional, Medina, Antonio, additional, Castellano, Ana, additional, Miranda, Yesica, additional, Fabre, Óscar, additional, García Polo, Iluminada, additional, Ibáñez, Patricia, additional, Sainz, Clara, additional, Sierra, Fernando, additional, Aragón, Esther, additional, Díaz, Jaime, additional, Aguilar, Fernando, additional, Ortega, María Ángeles, additional, Egido, José Antonio, additional, Pontes, José Carlos, additional, García, Miguel Ángel, additional, Cabrera, Francisco, additional, Batalla, Blanca, additional, Culla, Alex, additional, Molina, Carlos, additional, Flores, Alan, additional, Seró, Laia, additional, Muchada, Marian, additional, Meler, Pilar, additional, Boned-Riera, Sandra, additional, Cánovas, David, additional, Estela, Jordi, additional, Font, Juli, additional, Purroy, Francisco, additional, Benabdelhak, Ikram, additional, Sanahuja, Jordi, additional, Roquer, Jaume, additional, Rodríguez, Ana, additional, Ois, Ángel, additional, Cuadrado, Elisa, additional, Jiménez, Jordi, additional, Nogués, Xavier, additional, Kuprinski, Jerzy, additional, German, Antoni, additional, Irigoyen, Daniel, additional, Cara, Juan José, additional, Font, Maria Àngels, additional, Huertas, Sonia, additional, Martínez-Domeño, Alejandro, additional, Arroyo, Juan Antonio, additional, Delgado-Mederos, Raquel, additional, Gómez-Choco, Manuel Jesús, additional, Mengual, Juan José, additional, García, Sonia M., additional, Castellanos, M. del Mar, additional, van Eedenburg, Cecile, additional, Cañas, Imma, additional, Espinosa, Jordi, additional, Montull, Santiago, additional, Quesada, Helena, additional, Ustrell, Xavier, additional, Homedes, Christian, additional, Navalpotro, Irene, additional, Casanova, Jordi, additional, Lago, Aida Pilar, additional, Morata, Carmen, additional, Gorriz, David, additional, Moreno, Iván, additional, Tembl, José, additional, Ponz, Alejandro, additional, Fonseca, M. José, additional, Chamarro, Raquel, additional, Gil, Rosario, additional, Oliver, Vicente, additional, Pampliega, Ana, additional, Artero, Arturo, additional, Puchades, Francesc, additional, Landete, Lamberto, additional, Vilar, Carlos, additional, Jiménez, Carmen, additional, Vives, Bárbara, additional, Moragues, M. Dolores, additional, Díaz, Rosa, additional, Tur, Silvia, additional, Escribano, José Bernardo, additional, Lucas, César, additional, Martínez, Francisco, additional, Pons, José Miguel, additional, Romero, Amparo, additional, García, David, additional, Pérez, José, additional, Villaverde, Ramón, additional, Martínez, Salvadora, additional, Rodríguez, Aida, additional, Tejero, Carlos, additional, Pérez, Cristina, additional, Mostacero, Enrique, additional, Fernández, Covadonga, additional, Luna, Alain, additional, Pérez, Tomás, additional, González, Félix, additional, de Arce, Ana, additional, Martínez, Maite, additional, Díez, Noemí, additional, Gállego, Jaime, additional, Zandio, Beatriz, additional, Herrera, María, additional, Aymerich, Nuria, additional, Muñoz, Roberto, additional, Marta, Javier, additional, Artal, Jorge, additional, Errea, José M., additional, Timiraos, Juan José, additional, Moreno, M. Pilar, additional, Freijo, Mar, additional, García, Juan Manuel, additional, Gil, M. Carmen, additional, Revilla, M. Ángeles, additional, Palacio, Enrique, additional, Vázquez, José Luis, additional, Bestué, María, additional, Latorre, Ana, additional, Calvo, Eva, additional, Ballester, Laura, additional, Serrano, Marta, additional, Juega, Jesús M., additional, López, M. Ángeles, additional, Irimia, Pablo, additional, Imaz, Laura, additional, Fuentes, Blanca, additional, Sanz, Borja Enrique, additional, Beltrán, Luis, additional, Ruiz, Gerardo, additional, Martínez, Patricia, additional, Sánchez, Demetrio, additional, Barroso, Emilio, additional, Molina, Igor, additional, Budiño, Marco Antonio, additional, Masjuan, Jaime, additional, de Felipe, Alicia, additional, Matute, Consuelo, additional, Tejada, Javier, additional, Morán, Alberto, additional, Fernández, Esther, additional, Riveira, M. del Carmen, additional, Carnedo, Joaquín, additional, Manquillo, Antonio, additional, González, Raquel, additional, Fernández, José Carlos, additional, Guillan, Marta, additional, Yebra, Miguel, additional, Trejo, José M., additional, Saiz, Jesús, additional, Martínez-Acitores, Juan Carlos, additional, Bravo, Yolanda, additional, Arenillas, Juan Francisco, additional, Calleja, Ana, additional, Cortijo, Elisa, additional, Reyes, Javier, additional, López, Luis, additional, Muñoz, Pedro Luis, additional, Fidalgo, M. Ángeles, additional, Hernández, Jacinto, additional, Gómez, José Carlos, additional, Morán, José Carlos, additional, Gonzalo, Sonia, additional, Marrero, Jorge, additional, Satué, José Ángel, additional, Belinchón, Juan Carlos, additional, Moniche, Francisco, additional, Calderón, Enrique, additional, Escudero, Irene, additional, de la Torre, Javier, additional, Casado, Ignacio, additional, Antón, Joaquín, additional, Portilla, Juan Carlos, additional, Luengo, Juan, additional, Rosal, Joan, additional, Calzado, Elena, additional, Anglada, Juan Carlos, additional, Girón, Juan, additional, Ramírez, José M., additional, Pijierro, Agustín, additional, Roa, Ana, additional, Romero, Jorge, additional, Aguayo, Mariano, additional, Borrachero, Cristina, additional, Sanz, Gema, additional, Gómez, M. José, additional, Rico, Miguel Ángel, additional, Cayon, Antonio, additional, Carmona, Eduardo, additional, Cerro, Román, additional, López, Rafael, additional, Aguirre, Alfonso, additional, Lozano, Francisco, additional, and Rivera, José M., additional

Published
2018
Full Text
View/download PDF

97. Factores asociados al mal control de la anticoagulación con antivitamina K en pacientes con fibrilación auricular no valvular atendidos en consultas de Medicina Interna y Neurología. Estudio ALADIN

Author

Contreras Muruaga, M.M., primary, Reig, G., additional, Vivancos, J., additional, González, A., additional, Cardona, P., additional, Ramírez-Moreno, J.M., additional, Martí-Fábregas, J., additional, Suárez Fernández, C., additional, Pose, Antonio, additional, Díaz, José Antonio, additional, Rodríguez, Manuel, additional, Pena, Marta, additional, Arias, Susana, additional, Larrosa, Davinia, additional, González, Álvaro, additional, Rodríguez, Elisa, additional, González, Montserrat, additional, Fernández, Dolores, additional, Barbagelata, Cristina, additional, Raña, Natividad, additional, Freire, Santiago, additional, Cerqueiro, J. Manuel, additional, Guerrero, Héctor, additional, Ramos, Laura, additional, Álvarez, Leticia, additional, de Lis, José M., additional, Caro, Carmen, additional, Seijo, Manuel, additional, Mederer, Susana, additional, de Zarraga, Miguel Alberto, additional, Ferreiro, José, additional, Terrero, José M., additional, Arias, Mónica, additional, Pérez, Roberto, additional, Sánchez, Joaquín, additional, Maciñeiras, José, additional, Fernández, Julián, additional, Jaén, Fernando, additional, Esteva, David, additional, Zamora, Mónica, additional, Navarrete, Nuria, additional, García, Javier, additional, Mérida, Luis, additional, Corrales, Miguel Ángel, additional, Quirós, Raúl, additional, Cantero, Jesús, additional, Barrero, Francisco Javier, additional, Villegas, Inmaculada, additional, Castro, José, additional, Foronda, Jesús, additional, Carrillo, Dionisio, additional, Vega, Jesús, additional, Trujillo, José Antonio, additional, Montero, Manuel, additional, Jurado, Ana, additional, Sánchez, Carlos, additional, Agüera-Morales, Eduardo, additional, Sánchez, María, additional, Durán, Purificación, additional, Fernández de la Puerta, Rafael, additional, Pérez de la Blanca, María, additional, Martínez, María Paz, additional, Fernández, Óscar, additional, Tamayo, José Antonio, additional, Bustamante, Rafael, additional, Serrano, Pedro Jesús, additional, Arjona, Antonio, additional, Fernández, Javier, additional, Payan, Manuel, additional, Gómez, Ricardo, additional, Peña, Daniel, additional, Cabrerizo, Enrique, additional, Salgado, Fernando, additional, Ivanova Georgieva, Radka, additional, Gil-Núñez, Antonio, additional, Bello, Elena, additional, Díaz, Fernando, additional, Medina, Antonio, additional, Castellano, Ana, additional, Miranda, Yesica, additional, Fabre, Óscar, additional, García Polo, Iluminada, additional, Ibáñez, Patricia, additional, Sainz, Clara, additional, Sierra, Fernando, additional, Aragón, Esther, additional, Díaz, Jaime, additional, Aguilar, Fernando, additional, Ortega, María Ángeles, additional, Egido, José Antonio, additional, Pontes, José Carlos, additional, García, Miguel Ángel, additional, Cabrera, Francisco, additional, Batalla, Blanca, additional, Culla, Alex, additional, Molina, Carlos, additional, Flores, Alan, additional, Seró, Laia, additional, Muchada, Marian, additional, Meler, Pilar, additional, Boned-Riera, Sandra, additional, Cánovas, David, additional, Estela, Jordi, additional, Font, Juli, additional, Purroy, Francisco, additional, Benabdelhak, Ikram, additional, Sanahuja, Jordi, additional, Roquer, Jaume, additional, Rodríguez, Ana, additional, Ois, Ángel, additional, Cuadrado, Elisa, additional, Jiménez, Jordi, additional, Nogués, Xavier, additional, Kuprinski, Jerzy, additional, German, Antoni, additional, Irigoyen, Daniel, additional, Cara, Juan José, additional, Font, Maria Àngels, additional, Huertas, Sonia, additional, Martínez-Domeño, Alejandro, additional, Arroyo, Juan Antonio, additional, Delgado-Mederos, Raquel, additional, Gómez-Choco, Manuel Jesús, additional, Mengual, Juan José, additional, García, Sonia M., additional, Castellanos, M. del Mar, additional, van Eedenburg, Cecile, additional, Cañas, Imma, additional, Espinosa, Jordi, additional, Montull, Santiago, additional, Quesada, Helena, additional, Ustrell, Xavier, additional, Homedes, Christian, additional, Navalpotro, Irene, additional, Casanova, Jordi, additional, Lago, Aida Pilar, additional, Morata, Carmen, additional, Gorriz, David, additional, Moreno, Iván, additional, Tembl, José, additional, Ponz, Alejandro, additional, Fonseca, M. José, additional, Chamarro, Raquel, additional, Gil, Rosario, additional, Oliver, Vicente, additional, Pampliega, Ana, additional, Artero, Arturo, additional, Puchades, Francesc, additional, Landete, Lamberto, additional, Vilar, Carlos, additional, Jiménez, Carmen, additional, Vives, Bárbara, additional, Moragues, M. Dolores, additional, Díaz, Rosa, additional, Tur, Silvia, additional, Escribano, José Bernardo, additional, Lucas, César, additional, Martínez, Francisco, additional, Pons, José Miguel, additional, Romero, Amparo, additional, García, David, additional, Pérez, José, additional, Villaverde, Ramón, additional, Martínez, Salvadora, additional, Rodríguez, Aida, additional, Tejero, Carlos, additional, Pérez, Cristina, additional, Mostacero, Enrique, additional, Fernández, Covadonga, additional, Luna, Alain, additional, Pérez, Tomás, additional, González, Félix, additional, de Arce, Ana, additional, Martínez, Maite, additional, Díez, Noemí, additional, Gállego, Jaime, additional, Zandio, Beatriz, additional, Herrera, María, additional, Aymerich, Nuria, additional, Muñoz, Roberto, additional, Marta, Javier, additional, Artal, Jorge, additional, Errea, José M., additional, Timiraos, Juan José, additional, Moreno, M. Pilar, additional, Freijo, Mar, additional, García, Juan Manuel, additional, Gil, M. Carmen, additional, Revilla, M. Ángeles, additional, Palacio, Enrique, additional, Vázquez, José Luis, additional, Bestué, María, additional, Latorre, Ana, additional, Calvo, Eva, additional, Ballester, Laura, additional, Serrano, Marta, additional, Juega, Jesús M., additional, López, M. Ángeles, additional, Irimia, Pablo, additional, Imaz, Laura, additional, Fuentes, Blanca, additional, Sanz, Borja Enrique, additional, Beltrán, Luis, additional, Ruiz, Gerardo, additional, Martínez, Patricia, additional, Sánchez, Demetrio, additional, Barroso, Emilio, additional, Molina, Igor, additional, Budiño, Marco Antonio, additional, Masjuan, Jaime, additional, de Felipe, Alicia, additional, Matute, Consuelo, additional, Tejada, Javier, additional, Morán, Alberto, additional, Fernández, Esther, additional, Riveira, M. del Carmen, additional, Carnedo, Joaquín, additional, Manquillo, Antonio, additional, González, Raquel, additional, Fernández, José Carlos, additional, Guillan, Marta, additional, Yebra, Miguel, additional, Trejo, José M., additional, Saiz, Jesús, additional, Martínez-Acitores, Juan Carlos, additional, Bravo, Yolanda, additional, Arenillas, Juan Francisco, additional, Calleja, Ana, additional, Cortijo, Elisa, additional, Reyes, Javier, additional, López, Luis, additional, Muñoz, Pedro Luis, additional, Fidalgo, M. Ángeles, additional, Hernández, Jacinto, additional, Gómez, José Carlos, additional, Morán, José Carlos, additional, Gonzalo, Sonia, additional, Marrero, Jorge, additional, Satué, José Ángel, additional, Belinchón, Juan Carlos, additional, Moniche, Francisco, additional, Calderón, Enrique, additional, Escudero, Irene, additional, de la Torre, Javier, additional, Casado, Ignacio, additional, Antón, Joaquín, additional, Portilla, Juan Carlos, additional, Luengo, Juan, additional, Rosal, Joan, additional, Calzado, Elena, additional, Anglada, Juan Carlos, additional, Girón, Juan, additional, Ramírez, José M., additional, Pijierro, Agustín, additional, Roa, Ana, additional, Romero, Jorge, additional, Aguayo, Mariano, additional, Borrachero, Cristina, additional, Sanz, Gema, additional, Gómez, M. José, additional, Rico, Miguel Ángel, additional, Cayon, Antonio, additional, Carmona, Eduardo, additional, Cerro, Román, additional, López, Rafael, additional, Aguirre, Alfonso, additional, Lozano, Francisco, additional, and Rivera., José M., additional

Published
2018
Full Text
View/download PDF

99. Mechanical thrombectomy in orally anticoagulated patients with acute ischemic stroke

Author

Zapata-Wainberg, Gustavo, primary, Ximénez-Carrillo, Álvaro, additional, Trillo, Santiago, additional, Fuentes, Blanca, additional, Cruz-Culebras, Antonio, additional, Aguirre, Clara, additional, Alonso de Leciñana, María, additional, Vera, Rocío, additional, Bárcena, Eduardo, additional, Fernández-Prieto, Andrés, additional, Méndez-Cendón, José Carlos, additional, Caniego, Jose Luis, additional, Díez-Tejedor, Exuperio, additional, Masjuan, Jaime, additional, and Vivancos, José, additional

Published
2017
Full Text
View/download PDF

100. GRECOS Project (Genotyping Recurrence Risk of Stroke): The Use of Genetics to Predict the Vascular Recurrence After Stroke

Author

Fernandez-Cadenas, Israel, Mendióroz, Maite, Giralt, Dolors, Nafría, Cristina, Garcia, Elena, Carrera, Caty, Gallego-Fabrega, Cristina, Domingues-Montanari, Sophie, Delgado Martínez, María Pilar, Ribo, Marc, Castellanos, Mar, Martínez, Sergi, Freijo, Mari Mar, Jiménez-Conde, Jordi, Rubiera, Marta, Alvarez Sabín, José, Molina, Carlos A., Font, Maria Angels, Grau Olivares, Marta, Palomeras, Ernest, Pérez de la Ossa, Natalia, Martinez Zabaleta, Maite, Masjuan, Jaime, Moniche, Francisco, Cánovas, David, Piñana, Carlos, Purroy, Francisco, Cocho, Dolores, Navas, Inma, Tejero, Carlos, Aymerich, Nuria, Cullell, Natalia, Muiño, Elena, Serena, Joaquín, Rubio, Francisco, Dávalos, Antoni, Roquer González, Jaume, Arenillas, Juan F., Martí Fábregas, Joan, Keene, Keith, Chen, Wei-Min, Worrall, Bradford, Sale, Michele, Arboix, Adrià, Krupinski, Jerzy, Montaner, Joan, GRECOSstudy group, and Universitat Autònoma de Barcelona

Subjects
0301 basic medicine, Male, Risk, Candidate gene, recurrence, Genotype, Polymorphism, Single Nucleotide, Article, Brain Ischemia, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Polymorphism (computer science), Recurrence, Genetics, Medicine, risk factors, Humans, Genetic variability, Genotyping, Stroke, Aged, Advanced and Specialized Nursing, business.industry, Proportional hazards model, Stroke recurrence, Hazard ratio, medicine.disease, Prognosis, stroke, 030104 developmental biology, Scotland, Cardiovascular Diseases, Ischemic Attack, Transient, Spain, Cohort, North America, Female, Neurology (clinical), Cardiology and Cardiovascular Medicine, business, 030217 neurology & neurosurgery
Abstract

Altres ajuts: This study was funded by Marato TV3, by the Spanish stroke research network (INVICTUS-PLUS) and by Generacion project (PI15/01978) Instituto de Salud Carlos III. Dr Fernández-Cadenas is supported by the Miguel Servet program (CP12/03298), Instituto de Salud Carlos III. Several groups participate in the International Stroke Genetics Consortium and the Spanish Stroke Genetics Consortium. The Hospital del Mar is supported by Spain's Ministry of Health (III FEDER, RD12/0042/0020). Study recruitment and collection of data sets for the VISP trial were supported by a grant (R01 NS34447; PI James Toole) from the National Institute of Neurological Disorders and Stroke (NINDS). Genome-wide association studies genotyping (U01 HG004438l; PI David Valle), funded by the National Human Genome Research Institute and the Genomics and Randomized Trials (GARNET) Network (U01HG00516-03; co-PI Michèle M. Sale and Bradford B. Worrall), and genetic data cleaning was provided by the GARNET Coordinating Center (U01HG005157; PI Bruce S. Weir) Background and Purpose-Vascular recurrence occurs in 11% of patients during the first year after ischemic stroke (IS) or transient ischemic attack (TIA). Clinical scores do not predict the whole vascular recurrence risk, therefore we aimed to find genetic variants associated with recurrence that might improve the clinical predictive mode is in IS. Methods-We analyzed 256 polymorphisms from 115 candidate genes in three patient cohorts comprising 4,482 IS or TIA patients. The discovery cohort was prospectively recruited and included 1,494 patients, 6.2% of them developed a new IS during the first year of follow-up. Replication analysis was performed in 2,988 patients using SNPlex or HumanOmni1-Quad technology. We generated a predictive model using Cox regression (GRECOS score), and generated risk groups using a classification tree method. Results-The analyses revealed that rs1800801 in the MGP gene (HR: 1.33, p= 9×10−03), a gene related to artery calcification, was associated with new IS during the first year of follow-up. This polymorphism was replicated in a Spanish cohort (n=1.305), however it was not significantly associated in a North American cohort (n=1.683). The GRECOS score predicted new IS (p=3.2×10−09) and could classify patients, from low risk of stroke recurrence (1.9%) to high risk (12.6%). Moreover, the addition of genetic risk factors to the GRECOS score improves the prediction compared to previous SPI-II score (p=0.03). Conclusions-The use of genetics could be useful to estimate vascular recurrence risk after IS. Genetic variability in the MGP gene was associated with vascular recurrence in the Spanish population.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results